...
首页> 外文期刊>Journal of Clinical Microbiology >Development and Evaluation of a Dipstick Diagnostic Test for Neisseria meningitidis Serogroup X
【24h】

Development and Evaluation of a Dipstick Diagnostic Test for Neisseria meningitidis Serogroup X

机译:脑膜炎奈瑟氏菌血清群X的试纸诊断测试的开发和评估

获取原文
           

摘要

The emergence of Neisseria meningitidis serogroup X (NmX) in the African meningitis belt has urged the development of diagnostic tools and vaccines for this serogroup, especially following the introduction of a conjugate vaccine against N. meningitidis serogroup A (NmA). We have developed and evaluated a new rapid diagnostic test (RDT) for detecting the capsular polysaccharide (cps) antigen of this emerging serogroup. Whole inactivated NmX bacteria were used to immunize rabbits. Following purification by affinity chromatography, the cpsX-specific IgG antibodies were utilized to develop an NmX-specific immunochromatography dipstick RDT. The test was validated against purified cpsX and meningococcal strains of different serogroups. Its performance was evaluated against that of PCR on a collection of 369 cerebrospinal fluid (CSF) samples obtained from patients living in countries within the meningitis belt (Cameroon, C?te d'Ivoire, and Niger) or in France. The RDT was highly specific for NmX strains. Cutoffs of 105 CFU/ml and 1 ng/ml were observed for the reference NmX strain and purified cpsX, respectively. Sensitivity and specificity were 100% and 94%, respectively. A high agreement between PCR and RDT (Kappa coefficient, 0.98) was observed. The RDT gave a high positive likelihood ratio and a low negative likelihood (0.07), indicating almost 100% probability of declaring disease or not when the test is positive or negative, respectively. This unique NmX-specific test could be added to the available set of RDT for the detection of meningococcal meningitis in Africa as a major tool to reinforce epidemiological surveillance after the introduction of the NmA conjugate vaccine.
机译:非洲脑膜炎带中出现了脑膜炎奈瑟氏球菌血清群X(NmX),这催促了针对该血清群的诊断工具和疫苗的开发,尤其是在引入针对脑膜炎奈瑟氏菌血清群A(NmA)的结合疫苗之后。我们已经开发和评估了一种新的快速诊断测试(RDT),用于检测该新兴血清群的荚膜多糖(cps)抗原。整个灭活的NmX细菌用于免疫兔。通过亲和层析纯化后,利用cpsX特异性IgG抗体开发NmX特异性免疫层析试纸RDT。该测试针对纯化的cpsX和不同血清群的脑膜炎球菌菌株进行了验证。在从脑膜炎带国家(喀麦隆,科特迪瓦和尼日尔)或法国居住的患者中收集的369例脑脊液(CSF)样品中,对PCR的性能进行了评估。 RDT对NmX菌株具有高度特异性。对于参考NmX菌株和纯化的cpsX,分别观察到10 5 CFU / ml和1 ng / ml的临界值。敏感性和特异性分别为100%和94%。观察到PCR和RDT之间的高度一致性(Kappa系数为0.98)。 RDT给出高的阳性似然比和较低的阴性似然比(0.07),分别表示当测试为阳性或阴性时几乎100%宣布疾病的可能性。可以将这种独特的NmX特异性测试添加到可用的RDT中,以检测非洲的脑膜炎球菌性脑膜炎,作为在引入NmA结合疫苗后加强流行病学监测的主要工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号